News
Oct 16, 2025
At Porterhouse, we are proud to support World Amyloidosis Day. Our article shines a light on this rare condition to help drive greater understanding, improve…
Oct 14, 2025
Mohamad Mohty, Head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Sorbonne University, shared a post on X:“Join us for this…
Oct 07, 2025
AbstractTransthyretin (TTR) amyloidosis manifests in two distinct forms: hereditary (ATTRv) and wild-type transthyretin amyloidosis (ATTRwt). Despite being one of…
Oct 02, 2025
For many living with ATTR-CM amyloidosis, recent advances have brought hope. In just seven years we have gone from no approved treatments to having a number of…
Sep 25, 2025
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or…
Aug 14, 2025
Variant transthyretin (ATTRv) amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to amyloid fibril deposition. The Balearic…
Jul 29, 2025
AbstractThe accumulation of amyloid fibrils has been identified in tissues outside the brain, yet little is understood about the formation of extracerebral…
Jul 16, 2025
July 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a…
Jul 16, 2025
AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and…
Jul 16, 2025
AbstractBackgroundThe diagnosis of cardiac amyloidosis can be achieved noninvasively for transthyretin amyloid cardiomyopathy through nuclear scintigraphy with bone…